Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
Artur Martins Novaes CoutinhoGeraldo F BusattoFábio Henrique de Gobbi PortoDaniele de Paula FariaCarla Rachel OnoAlexandre Teles GarcezPaula SquarzoniFábio Luiz de Souza DuranMaira Okada de OliveiraEduardo Sturzeneker TresSonia Maria Dozzi BruckiOrestes Vicente ForlenzaRicardo NitriniCarlos Alberto BuchpiguelPublished in: European journal of nuclear medicine and molecular imaging (2020)
The PET-based staging system unveiled significant A(N) differences between AD and the other groups, whereas aMCI and controls had different (N) staging, explaining the cognitive impairment in aMCI. [18F]FDG-PET could be used beyond simple (N) staging, since it provided alternative hypotheses to cases with clinical-biomarker "mismatches." An AD hypometabolic pattern correlated with amyloid positivity. Low education and SES were related to dementia in the absence of biomarker changes.